bupropion has been researched along with Depressive Disorder, Treatment-Resistant in 16 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Excerpt | Relevance | Reference |
|---|---|---|
| "US Clinical Trials registration was systematically searched for studies examining the effects of dextromethorphan in mood disorders." | 9.41 | Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence. ( Iosifescu, DV; Parincu, Z, 2023) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 8.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "US Clinical Trials registration was systematically searched for studies examining the effects of dextromethorphan in mood disorders." | 5.41 | Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence. ( Iosifescu, DV; Parincu, Z, 2023) |
| "Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019." | 4.12 | Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022) |
| "Patients diagnosed with PTSD showed more severe depressive symptoms at baseline and were less likely to achieve either remission or response by 12 weeks." | 2.94 | Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. ( Aslam, M; Chen, P; Davis, L; Hicks, PB; Iranmanesh, A; Johnson, GR; Jurjus, G; Lauro, K; Michalets, J; Mohamed, S; Pilkinton, P; Rao, SD; Sapra, M; Sevilimedu, V; Thase, M; Wilcox, JA; Zisook, S, 2020) |
| "Approximately 50% of patients with major depressive disorder do not respond adequately to their antidepressant treatment, underscoring the need for more effective treatment options." | 2.84 | Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. ( Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E, 2017) |
| "Overall, both treatments significantly improved depressive symptoms without causing serious adverse events." | 2.84 | Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. ( Cheon, EJ; Koo, BH; Lee, JH; Lee, KH; Lee, SJ; Park, YW; Sung, HM, 2017) |
| "Bupropion is an antidepressant agent usually reserved as an augmentation strategy for treatment-resistant depression." | 1.42 | Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram. ( Balasubramanian, T; Ferraro, A; Wiggins, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, J | 1 |
| Halaris, A | 1 |
| Parincu, Z | 1 |
| Iosifescu, DV | 1 |
| Ebell, MH | 1 |
| Mohamed, S | 2 |
| Johnson, GR | 2 |
| Sevilimedu, V | 1 |
| Rao, SD | 1 |
| Hicks, PB | 1 |
| Chen, P | 2 |
| Lauro, K | 1 |
| Jurjus, G | 1 |
| Pilkinton, P | 1 |
| Davis, L | 1 |
| Wilcox, JA | 2 |
| Iranmanesh, A | 2 |
| Sapra, M | 2 |
| Aslam, M | 1 |
| Michalets, J | 1 |
| Thase, M | 1 |
| Zisook, S | 2 |
| Weissman, CR | 1 |
| Hadas, I | 1 |
| Yu, D | 1 |
| Jones, B | 1 |
| Kong, D | 1 |
| Mulsant, BH | 2 |
| Blumberger, DM | 2 |
| Daskalakis, ZJ | 1 |
| Cristancho, P | 1 |
| Lenard, E | 1 |
| Lenze, EJ | 1 |
| Miller, JP | 1 |
| Brown, PJ | 1 |
| Roose, SP | 1 |
| Montes-Garcia, C | 1 |
| Lavretsky, H | 2 |
| Rollman, BL | 1 |
| Reynolds, CF | 1 |
| Karp, JF | 1 |
| Wiggins, A | 1 |
| Balasubramanian, T | 1 |
| Ferraro, A | 1 |
| Liu, YW | 1 |
| Chang, C | 1 |
| Chen, TY | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Tzeng, NS | 1 |
| Fawcett, J | 1 |
| Rush, AJ | 1 |
| Vukelich, J | 1 |
| Diaz, SH | 1 |
| Dunklee, L | 1 |
| Romo, P | 1 |
| Yarns, BC | 1 |
| Escalona, R | 1 |
| Tal, I | 1 |
| Weingart, K | 1 |
| Hicks, P | 1 |
| Davis, LL | 1 |
| Yoon, J | 1 |
| Vertrees, JE | 1 |
| Rao, S | 1 |
| Pilkinton, PD | 1 |
| Huang, GD | 1 |
| Arandjelovic, K | 1 |
| Eyre, HA | 1 |
| Li, QS | 1 |
| Tian, C | 1 |
| Seabrook, GR | 1 |
| Drevets, WC | 1 |
| Narayan, VA | 1 |
| Fava, M | 1 |
| Okame, T | 1 |
| Matsushima, Y | 1 |
| Perry, P | 1 |
| Weiller, E | 1 |
| Baker, RA | 1 |
| Cheon, EJ | 1 |
| Lee, KH | 1 |
| Park, YW | 1 |
| Lee, JH | 1 |
| Koo, BH | 1 |
| Lee, SJ | 1 |
| Sung, HM | 1 |
| Gaynes, BN | 1 |
| Dusetzina, SB | 1 |
| Ellis, AR | 1 |
| Hansen, RA | 1 |
| Farley, JF | 1 |
| Miller, WC | 1 |
| Stürmer, T | 1 |
| Quante, A | 1 |
| Zeugmann, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)[NCT01421342] | Phase 3 | 1,522 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.[NCT03473431] | 90 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adju[NCT02012218] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Relapse in symptoms of major depression defined as a QIDS-C16 => 11 among those achieving remission in the acute phase. (NCT01421342)
Timeframe: Within 36 weeks after randomization (initiation of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 26 |
| Augmenting: Antidepressant + Bupropion-SR | 35 |
| Augmenting: Antidepressant + Aripiprazole | 37 |
Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of <= 5 for two consecutive visits. (NCT01421342)
Timeframe: During acute phase (12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 114 |
| Augmenting: Antidepressant + Bupropion-SR | 136 |
| Augmenting: Antidepressant + Aripiprazole | 146 |
Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 319 |
| Augmenting: Antidepressant + Bupropion-SR | 332 |
| Augmenting: Antidepressant + Aripiprazole | 375 |
Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved). (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 356 |
| Augmenting: Antidepressant + Bupropion-SR | 376 |
| Augmenting: Antidepressant + Aripiprazole | 400 |
"The MADRS was used as the primary efficacy assessment of level of depression. The MADRS was administered using the Structured Interview Guide for the MADRS. Detailed instructions were provided.The MADRS consists of 10 items each, with 7 defined grades of severity (ie, 0 to 6, with 0 being the best rating and 6 being the worst rating). The MADRS total score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score least squares (LS) mean changes from baseline to Week 6 is mentioned below." (NCT02012218)
Timeframe: Baseline and Week 6
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Group 1A | -12.8 |
| Group 1B | -18.4 |
| Group 2 | -19.5 |
| Group 3 | -19.2 |
| Group 4 | -16.8 |
1 review available for bupropion and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence.
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2023 |
6 trials available for bupropion and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depre | 2020 |
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized.
Topics: Aged; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Treatment-Resistant; Huma | 2019 |
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Bupropion; Comorbidity; Depress | 2016 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depres | 2017 |
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depressive Disorde | 2017 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; | 2012 |
9 other studies available for bupropion and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methy | 2022 |
Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
Topics: Aged; Aripiprazole; Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Humans; Nortrip | 2023 |
Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2021 |
Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram.
Topics: Aged; Antidepressive Agents; Bupropion; Citalopram; Confusion; Depressive Disorder, Treatment-Resist | 2015 |
Refractory depression with catatonic features was remitted with administration of intravenous dopamine and consequent bupropion as maintenance treatment.
Topics: Administration, Intravenous; Aged; Antidepressive Agents, Second-Generation; Bupropion; Catatonia; D | 2016 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; | 2016 |
Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attitude of Health Personnel; Bupro | 2016 |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
Topics: Adult; Antidepressive Agents; Bupropion; Chromosomes, Human, Pair 4; Circadian Rhythm; Citalopram; D | 2016 |
Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Treatment-Resistant; Drug | 2012 |